Cargando…
P990: T CELL RESPONSE AND OMICRON VARIANT NEUTRALISATION FOLLOWING VACCINATION AGAINST SARS-COV-2 IN PATIENTS WITH CHRONIC MYELOID DISORDERS
Autores principales: | Harrington, P., Saunders, J., Saha, C., Sheikh, A., Dillon, R., Raj, K., Cadman-Davies, L., Lechmere, T., Khan, H., Woodley, C., Asirvatham, S., Curto-Garcia, N., O’Sullivan, J., Kordasti, S., Radia, D., McLornan, D., Malim, M., Doores, K., Harrison, C., de Lavallade, H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430025/ http://dx.doi.org/10.1097/01.HS9.0000846828.97717.5d |
Ejemplares similares
-
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders
por: Harrington, Patrick, et al.
Publicado: (2022) -
P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
por: Harrington, P., et al.
Publicado: (2022) -
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
por: Harrington, Patrick, et al.
Publicado: (2021) -
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia
por: Harrington, Patrick, et al.
Publicado: (2021) -
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
por: Harrington, Patrick, et al.
Publicado: (2022)